Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
“The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.
- “The Company’s progress is clear, and the impact of the changes we have made will continue to move us forward.
- (Fix) Selling, general and administrative expenses were down 36% in the first quarter of 2023, compared to the same period in 2022.
- (Fund/Propel) The Company launched its Strategic Partnership Initiative focused on developing long-term licensing revenue opportunities in Q3 2023.
- “Our journey and our focus is to advance innovative technology to market, and to deliver value to our stockholders."